Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 10214586 PD-L1 antibodies

Patent 10214586 was granted and assigned to Eli Lilly and Company on February, 2019 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

0

Patent attributes

Patent Applicant

0

Current Assignee

0

Patent Jurisdiction

United States Patent and Trademark Office

0

Patent Number

Patent Inventor Names

Yiwen Li0

Dale Lincoln Ludwig0

Juqun Shen0

Marshall Davenport Snavely0

Vera Molkenthin0

Date of Patent

February 26, 2019

0

Patent Application Number

152399590

Date Filed

August 18, 2016

0

Patent Citations Received

US Patent 11779604 Antibodies, combinations comprising antibodies, biomarkers, uses and methods

US Patent 10604576 Antibodies and immunocytokines

0

US Patent 11753479 Nucleic acids encoding anti-OX40L antibodies

US Patent 11773175 Antibodies, uses and methods

Patent Primary Examiner

Ilia I Ouspenski

0

Patent abstract

The present invention relates to antibodies that bind human programmed cell death 1 ligand 1 (PD-L1), and may be useful for treating solid and hematological tumors alone and in combination with chemotherapy and other cancer therapeutics.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 10214586 PD-L1 antibodies

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool